CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs

ConclusionsBalancing the data presented in the current manuscript with additional data concerning long term safety on the one hand and cost issues on the other hand, can be of particular use to health policy makers to implement this new drug class in the prevention of migraine.
Source: The Journal of Headache and Pain - Category: Neurology Source Type: research